NCT03755804 2026-02-23
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT04685616 2026-02-18
RADAR
University College, London
Phase 3 Recruiting
NCT03033914 2026-02-17
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT04225390 2026-02-10
PROMIT
University of Erlangen-Nürnberg Medical School
Phase 2 Completed
NCT06835049 2025-12-30
TNT-HYPE
Swiss Cancer Institute
Phase 2 Recruiting
NCT06984146 2025-11-26
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Recruiting
NCT07002216 2025-11-03
BrECADD
University of Miami
Phase 2 Recruiting
NCT05922904 2025-10-10
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03805022 2025-10-02
CIRSARC
Institut Bergonié
Phase 3 Recruiting
NCT03159897 2025-08-08
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Fondazione Italiana Linfomi - ETS
Phase 3 Completed
NCT03331341 2025-08-05
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
University of Washington
Phase 1/2 Completed
NCT01868451 2025-07-09
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT06377566 2025-04-20
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting